Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for neurological disorders with significant unmet medical need. The company operates within the biopharmaceutical and neuroscience drug development industries, with a scientific emphasis on targeting receptor-associated protein complexes in the brain to achieve greater therapeutic selectivity. Rapport Therapeutics does not have any approved products and does not generate commercial revenue as of its most recent public filings.
The company’s primary value driver is its pipeline of small‑molecule therapeutics designed to modulate specific neural signaling pathways implicated in disorders such as epilepsy and other central nervous system conditions. Rapport Therapeutics is positioned around a differentiated platform that seeks to improve efficacy and safety compared to broadly acting neurological drugs. The company was founded in 2020 and launched with backing from Third Rock Ventures, subsequently advancing its lead program into clinical development and completing an initial public offering on the Nasdaq under the ticker RAPP.
Business Operations
Rapport Therapeutics’ operations are centered on research and development activities, with revenue generation expected only through future product commercialization or potential strategic partnerships. Its core business consists of internal discovery, preclinical research, and clinical development of targeted neurological therapies, supported by outsourced manufacturing and clinical trial services. The company’s lead development candidate, RPT‑01, is being evaluated for the treatment of focal epilepsy and is designed as a selective modulator of AMPA receptor signaling.
The company operates primarily in the United States, with research, clinical, and corporate functions concentrated domestically. Rapport Therapeutics controls its proprietary discovery platform and intellectual property related to receptor-associated protein targeting. As of the latest available public disclosures, the company has no material subsidiaries and has not announced major joint ventures; collaboration activity is limited and data inconclusive based on available public sources.
Strategic Position & Investments
Rapport Therapeutics’ strategy is focused on advancing its lead clinical program while expanding its pipeline through internal discovery efforts targeting additional neurological indications. Growth initiatives emphasize disciplined capital deployment, milestone-driven clinical development, and maintaining optionality for future partnerships. The company has invested primarily in its internal R&D capabilities rather than external acquisitions.
The firm has not disclosed any completed mergers or acquisitions since inception, and its investment profile is concentrated in early- to mid-stage clinical assets. Emerging areas of focus include precision neurology approaches that leverage synaptic biology to improve therapeutic specificity. Beyond its wholly owned development programs, no material portfolio companies or strategic equity investments have been publicly confirmed.
Geographic Footprint
Rapport Therapeutics is headquartered in Boston, Massachusetts, a major hub for biotechnology and life sciences innovation. Its operational footprint is primarily concentrated in the United States, where it conducts research activities and manages clinical development programs.
While the company does not maintain significant international facilities, its clinical trials may involve investigational sites outside the U.S., consistent with standard industry practices. International operational influence remains limited, and the company does not currently report material revenue or assets located outside North America.
Leadership & Governance
Rapport Therapeutics is led by an experienced management team with backgrounds in neuroscience, drug development, and biotechnology company building. The leadership team emphasizes a strategy of scientific rigor, precision medicine, and long-term value creation through differentiated neurological therapies.
Key executives include:
- Abe Ceesay, M.D., Ph.D. – Chief Executive Officer
- Stephan Scherer, Ph.D. – Chief Scientific Officer
- Alex DeBoyace – Chief Financial Officer
The company is governed by a board of directors that includes representatives with venture capital, pharmaceutical, and clinical expertise. Leadership philosophy, as reflected in public statements and filings, centers on targeted innovation in neuroscience and disciplined clinical execution.